newsfilter
← Latest News
GlobeNewswire·

DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasisTopline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy